NCT04862949View on ClinicalTrials.gov

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

CompletedOBSERVATIONAL

Enrollment

124

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

March 9, 2023

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Atezolizumab plus bevacizumab

Atezolizumab plus bevacizumab

Trial Locations (1)

13496

Cha Medical Center, Seongnam-si

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

CHA University

OTHER